



Press Release, October 26. 2020

Article on RhoVac's Phase I/II study to be published in November

Lund, October 26, 2020. RhoVac AB ("RhoVac") announces today that the publication of the article on RhoVac's Phase I/II study is set to be published in November.

As previously disclosed, the article elaborating on the results of RhoVac's Phase I/II study in prostate cancer including the 12-month follow-up period, has been accepted for publication in the *Journal for ImmunoTherapy of Cancer* (JITC). The publication now indicates that the release of the article will take place in November, a few weeks later than previously suggested. The article will feature an elaboration on the mode of action of RV001, but also a discussion on the PSA data findings indicating possibilities of delaying disease progression, for which RhoVac's currently ongoing phase IIb study is aimed at providing substantial evidence.

RhoVac's CEO, Anders Måansson, comments: "Despite the minor delay, I am very happy about the confirmation on the publication of this article. We have waited for this publication a long time, and now and I am excited to address its findings with our potential partners."

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 26. 2020 at 08:30.

For more information, please contact:

Anders Måansson – CEO, RhoVac AB
Telefon: +46 73 751 7278
E-post: info@rhovac.com

On RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is launching a clinical phase IIb trial that will include at least 175 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumour. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.